Category Archives: Growth Investing

Celgene: A Growth Stock You Don’t Wanna Miss

Despite having appreciated 20% in a year, Celgene Corporation (NASDAQ:CELG) shares are still a reasonable buy for growth.

What does Celgene do?

Celgene is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for patients with cancer, immune-inflammatory, and other unmet medical needs. The company operates in more than 60 countries and sells its products in more than 70.

In 2016, Celgene generated sales of $11.2 billion. Its expertise lies in hematology, oncology, and immunology. Here’s an overview of Celgene’s key products:

Product 2016 Sales (million) % of 2015 Sales % of 2016 Sales YOY growth
Revlimid $6,974 63% 62% +20%
Pomalyst/Imnovid $1,311 11% 11.7% +33%
Otezla $1,017 5% 9% +116%
Abraxane $973 10% 8.7% +1%
91.4%

Revlimid remains as Celgene’s core drug from 2015 and its market in the multiple myeloma space is still growing.

Read More

Spin Master Corp: A Gem With Great Growth Potential

Spin Master Corp’s (TSX:TOY) 10% pullback in the last five days due to the bad press from Hatchimal complaints could be a long-term buying opportunity. After all, the children’s entertainment company is not a one-trick pony; it has a diverse portfolio of products. Further, it has passionate and capable management. It has won multiple awards across different product categories and has made successful acquisitions.

Spin Master PAW Patrol

Photo: Televisione Streaming. License: CC by 2.0. Source: flickr


Read More